Protection Against Pneumococcal Infection in Children With T1DM

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Children/ young people with diabetes may be at a higher risk of acquiring certain infections. These infections include those caused by a bacterium called the pneumococcus which can cause pneumonia, meningitis and ear infections. In the UK older children with diabetes are given a vaccine against the pneumococcus bug called Pneumovax (or PPS23 for short). Although PPS23 causes a good immune response in children over 2 years of age it is not actually known how well PPS23 protects against infection in children of any age. In addition there is some data in adults and children that PPS23 may result in a reduced response to future doses of pneumococcal vaccines (hyporesponsiveness). Because of the lack of information on how well PPS23 protects and potential hyporesponsiveness the investigators would like to study the use of an alternative vaccine against pneumococcus called Prevenar13 (or pCV13). This vaccine is known to be safe and to work well in babies and young children and there have been no concerns about hyporesponsiveness. It has been approved for use in children up to 17 years of age but there is little information on the size and duration of immune response to PCV13 in children aged 6 years and older.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13

NCT05408429

Pneumococcal Disease

COMPLETED PHASE3

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

NCT00366899

Vaccines, Pneumococcal

COMPLETED PHASE3

Understanding Pneumococcal Carriage and Disease 2017-2020

NCT03102840

Streptococcus Pneumoniae Infection Streptococcus Pneumoniae, Invasive Disease Streptococcal Pneumonia

UNKNOWN

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

NCT00824655

Pneumococcal Vaccines

COMPLETED PHASE3

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months

NCT06622109

Pneumococcal Disease

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prevenar13® (13-valent pneumococcal conjugate vaccine)

Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.

Group Type EXPERIMENTAL

13-valent pneumococcal conjugate vaccine (PCV13)

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

13-valent pneumococcal conjugate vaccine (PCV13)

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prevenar13®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of T1DM and being followed in the Oxfordshire Children's Diabetes Service.
* Aged between 6 years and 17 years.
* Parent/legal guardian willing and able to give informed consent.
* No previous immunisation with a pneumococcal conjugate vaccine (PCV).
* Willing to allow the General Practitioner to be notified of participation in the study.

Exclusion Criteria

* Known allergic reaction to the vaccine antigen or any of the excipients.
* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.

Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No